EFTISARC-NEO is a single-arm phase II trial from Warsaw asking whether an immune-priming agent can deepen the response to preoperative radiotherapy in high-risk soft tissue sarcoma. Eftilagimod alfa (efti), a soluble LAG-3 protein that activates antigen-presenting cells, was added to pembrolizumab and standard 50 Gy preoperative radiotherapy before surgery — a chemotherapy-free regimen. The pathological response data were striking at ESMO 2025; the first survival data, presented at CTOS 2026, are encouraging but come with the limits of a small, single-arm, single-centre study.
EFTISARC-NEO at a glance
81.1%
disease-free survival at 12 months (38 patients resected; median follow-up 19.1 months)
51.5%
median tumour hyalinisation/fibrosis, the primary endpoint (prespecified target 35%; historical radiotherapy alone ~15%)
94.1%
local recurrence-free survival at 12 months
40
patients enrolled (single arm, single centre; 38 underwent surgery)
The question
- Can activating antigen-presenting cells with efti, alongside PD-1 blockade and radiotherapy, convert the immunosuppressed sarcoma microenvironment and improve pathological response and disease control?
- Efti is a soluble LAG-3 protein and MHC class II agonist: it activates antigen-presenting cells, priming CD8+ T-cell responses — mechanistically upstream of, and complementary to, pembrolizumab.
Design
- Investigator-initiated, open-label, single-arm, single-stage phase II trial (NCT06128863), led by the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Principal investigators: Katarzyna Kozak and Paweł Sobczuk. Funded mainly by the Polish Medical Research Agency; efti supplied by Immutep.
- Enrolment July 2023 to January 2025 (40 patients). Primary endpoint reported at ESMO 2025 (proffered paper); survival update at CTOS 2026 (poster P448), data cut-off 30 April 2026.
The regimen (chemotherapy-free, ~11–12 weeks)
- Eftilagimod alfa 30 mg subcutaneously every 2 weeks × 5 (weeks 1, 3, 5, 7, 9).
- Pembrolizumab 200 mg intravenously every 3 weeks × 3 (weeks 1, 4, 7).
- Radiotherapy 50 Gy in 25 fractions over 5 weeks (weeks 2–6), concurrent with the systemic therapy.
- Surgery in weeks 11–12.
Who was enrolled
- High-risk, resectable soft tissue sarcoma of the extremity or trunk: grade 2–3, primary tumour ≥5 cm, or locally recurrent tumour of any size; ECOG 0–1.
- Median age 54.5 years; median tumour size 8.8 cm; 40% grade 3; five sarcoma subtypes represented.
Endpoints
- Primary: pathological response — percentage of tumour hyalinisation/fibrosis at resection (designed to detect an improvement from a historical 15% with radiotherapy alone to 35%).
- Secondary: safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response, quality of life.
Results — pathological response (ESMO 2025)
- Primary endpoint met: median tumour hyalinisation/fibrosis 51.5% (IQR 15–76; p<0.001), well above the 35% target and the ~15% historical figure for radiotherapy alone.
- Median residual viable tumour was 12.5%.
Results — survival (CTOS 2026, median follow-up 19.1 months)
- Disease-free survival 81.1% at 12 months; the Kaplan–Meier estimate at 18 months is also 81.1% but is immature.
- Local recurrence-free survival 94.1% and distant metastasis-free survival 86.2% at 12 months.
- 8 of 38 resected patients had recurred by the data cut-off.
Biomarker signals (exploratory)
- Post-treatment tumour-infiltrating lymphocytes above 310 cells/mm²: 12-month DFS 95.0% vs 64.9% at or below that level.
- Hyalinisation/fibrosis above 52%: 12-month DFS 93.8% vs 71.4%.
- Tertiary lymphoid structures, and baseline PD-L1, LAG-3 and TIGIT expression, did not correlate with survival.
Safety
- At ESMO 2025 the combination was reported to have a manageable safety profile; a detailed toxicity breakdown has not been released with the CTOS 2026 survival update.
Where this sits
- The randomised anchor for immunotherapy + radiotherapy in this disease is SU2C-SARC032 (Lancet 2024): adding perioperative pembrolizumab to preoperative radiotherapy and surgery improved 2-year DFS from 52% to 67% (HR 0.61) in stage III undifferentiated pleomorphic sarcoma and pleomorphic/dedifferentiated liposarcoma.
- EFTISARC-NEO goes one step further — adding an antigen-presenting-cell activator, across broader histologies, without chemotherapy — but without a control arm.
What it doesn’t prove
- Single arm, 40 patients, one centre: every comparison is against historical controls, and patient selection can flatter the results.
- The primary endpoint is a pathological surrogate, not survival; DFS beyond 12 months is still immature, and overall survival has not been reported.
- The TIL and hyalinisation cut-offs are exploratory, post-treatment analyses — hypothesis-generating, not yet a selection tool.
- The survival data are currently available as a sponsor press release of a conference poster; the full peer-reviewed paper is awaited.
- Efti is not approved for soft tissue sarcoma (it holds FDA orphan drug designation in this disease). A registration-directed trial is being prepared, targeted to start in the second half of 2027.
Bottom line for practice
- A coherent, biologically consistent signal: deeper pathological response, high early local control, and outcomes tracking with the degree of immune infiltration the regimen induces.
- Not practice-changing yet. For now it strengthens the case for perioperative immunotherapy–radiotherapy combinations in high-risk soft tissue sarcoma and for trials that stratify by immune response — the randomised efti trial, if it proceeds, is the one to watch.
Key sources
- Immutep press release, 19 November 2026 (GlobeNewswire): EFTISARC-NEO survival data presented at CTOS 2026 (poster P448); data cut-off 30 April 2026.
- Kozak K et al. EFTISARC-NEO primary endpoint results, ESMO Congress 2025 (proffered paper); Immutep press release, 20 October 2025.
- ClinicalTrials.gov NCT06128863.
- Mowery YM et al. SU2C-SARC032: pembrolizumab, radiation therapy, and surgery vs radiation therapy and surgery for stage III soft tissue sarcoma of the extremity. Lancet 2024;404:2053–2064.